On 18 December 2009, the [[European Medicines Agency]] (EMA) recommended the withdrawal of all medicines containing benfluorex in the [[European Union]], because their risks, particularly the risk of [[heart valve disease]] (fenfluramine-like cardiovascular side-effects), are greater than their benefits.<ref>{{ cite web | title = European Medicines Agency recommends withdrawal of benfluorex from the market in European Union | url = http://www.emea.europa.eu/pdfs/human/referral/benfluorex/Benfluorex_81503309en.pdf | format = pdf | publisher = European Medicines Agency | date = 2009-12-18 }}</ref> Thus Frachon ''et al.'' showed a significantly higher prevalence of unexplained valvular [[cardiovascular disease|heart disease]] in patients taking benfluorex compared to controls.<ref>{{Cite journal
